ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure ImprovementsPRNewsWire · Oct 8, 2026
These beaten-down stocks could bounce back in January, if history is any guideMarket Watch · Sep 21, 2026
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferencePRNewsWire · Sep 3, 2026
ADC Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 13, 2026
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 13, 2026
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research · Aug 13, 2026ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.22 | -$0.11 | Beat |
| May 4, 2026 | -$0.19 | -$0.21 | Miss |
| Mar 10, 2026 | -$0.32 | -$0.04 | Beat |
| Nov 10, 2025 | -$0.40 | -$0.30 | Beat |
| Aug 12, 2025 | -$0.36 | -$0.50 | Miss |
| May 14, 2025 | -$0.38 | -$0.36 | Beat |